Please note Chef Michelle Bernstein is a COSENTYX® (secukinumab) patient and has been compensated for her time. Continue reading for Important Safety Information and a link to the full ...

Please note NiYondashay is a COSENTYX ® (secukinumab) patient and has been compensated for her time. Continue reading for Important Safety Information and a link to the full Prescribing ...

GlobalData expects Tremfya to steal patient share from Cosentyx, with the potential for IL-23 inhibitors to surpass patient share and sales of IL-17 inhibitors by 2027 despite entering the ...

Novartis’ Cosentyx (secukinumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderate-to-severe hidradenitis suppurativa (HS). The decision makes the IL-17A ...

This approval makes Cosentyx the first interleukin-17A inhibitor and second biologic approved for hidradenitis suppurativa. Approval was supported by positive results from SUNSHINE and SUNRISE ...